Navigation Links
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
Date:9/17/2008

FREMONT, Calif., Sept. 17 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced the presentation of posters at the 5th Annual RNAi Europe, taking place September 16-18, 2008 in Stockholm, Sweden. Three of Quark's scientists, Igor Mett, Hagar Kalinski, and Hagit Ashush, presented posters highlighting development of specific proprietary molecular tools facilitating target discovery, generation of potent RNAi therapeutics, and analysis of their activity and delivery in the framework of Quark's pre-clinical RNAi research.

A poster submitted by Hagar Kalinski is titled "Evaluation of siRNA Uptake in vivo in Target Tissues Using PCR-Based Quantification or in-situ Hybridization." It describes methods for analyzing spatial distribution of synthetic siRNA in target organs and tissues, including kidneys, lungs, retinas, and spinal cords, in an in vivo animal models. The quantification of siRNA delivery to target tissues and the ability to determine its cell-specific localization facilitates siRNA therapeutic development.

"Construction of Complex RNAi Libraries for Positive and Negative Phenotypic Selection of Target Genes," a poster submitted by Igor Mett, describes several of Quark's approaches to generating expressed RNAi libraries that are compatible with microarray-based positive and negative phenotypic cell selection. Part of the continuing development of Quark's BiFAR target discovery platform, these complex libraries can provide a high throughput tool to help identify targets for siRNA therapeutic development.

A third poster, submitted by Hagit Ashush, is titled "Tandem and RNAstar molecules for simultaneous silencing several genes," and evaluates the potential of complex dsRNA structures targeting two ("tandem") or three ("RNAstar") different genes in vitro. The multigene nature of pathogenesis for different diseas
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
9. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The next-generation ... several key market segments, including the molecular diagnostics industry. BCC Research reveals in its ... of NGS-based tests, lower test costs, and a growing need for better diagnostics as ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... A newly ... new ideas to lower the barriers to innovation in life sciences R&D. The Pistoia ... to two cash prizes of US$15,000 and a period of expert mentorship from a ...
(Date:6/30/2015)... , July 1, 2015 R-Japan Co.,Ltd. obtained ... the Safety of Regenerative Medicine from the Ministry of Health, ... June 29, 2015. The fact that R- ... facility through the auditing from Pharmaceuticals and Medical Devices Agency ... application, allows it to provide stem cell manufacturing service to ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... May 16 Stereotaxis, Inc. (Nasdaq:,STXS), announced today ... at the Seventh Annual JMP Securities Research Conference ... 12:00 p.m. Pacific Time., Attendance at the ... be webcast live and remain available for 90 ...
... WAYNE, N.J. and EMERYVILLE, Calif., May 16 ,Bayer ... ONXX ) today announced more than 40 data ... (ASCO) annual meeting demonstrating,the potential for Nexavar(R) (sorafenib) ... or in combination with other agents., "Data ...
... - Revenues from Product Sales Increased 149% to $3.5 Million ... - ... May 15 AMDL, Inc. (Amex: ADL ),is a ... in Shenzhen, Jiangxi and Jilin,China. Through its wholly owned subsidiary ...
Cached Biology Technology:Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 4Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 5Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 6Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 7AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 2AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 3
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
(Date:6/23/2015)...   Valencell, a leader in performance ... recent study that illustrates its PerformTek biometric technology ... In a study conducted at Valencell,s Biometric Lab, ... Apple Watch against a chest strap – the ... The study demonstrated that Valencell,s biometric technology delivers ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... of smoking and leisure time exercise, vitamin E supplementation may ... risk of pneumonia, according to a study published in ... influenced the immune system. In several animal studies vitamin E ... vitamin E on human infections is not known. Dr. ...
... European Molecular Biology Organization (EMBO) and the Federation of ... of Chemistry at the University of Oxford, UK, as ... Award. Professor Robinson has been recognized for her pioneering ... tool used for investigating the structure and dynamics of ...
... Spanish . A study conducted at the ... Cecilio revealed that preterm mothers, milk contains low concentrations of coenzyme ... to its antioxidant capacity and to its role as a component ... counted with the participation of a group of researchers of the ...
Cached Biology News:2011 FEBS/EMBO Women in Science Award honors Carol V. Robinson 2Preterm mothers' milk contains less antioxidants than mothers completing their gestation 2